$ADTX

ADITXT INC

Pharmaceutical preparations · Pink Limited

0.005 -60.00% as of 9/20/2026, 12:08:39 PM · delayed

Sentiment

BULLISH BEARISH

No open positions yet.

No threads yet for $ADTX. Be the first to post.

Official links

Filings

8-K Thu Oct 15 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
25-NSE Wed Oct 07 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov
8-K Wed Sep 23 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
8-K Wed Aug 19 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
8-K Fri Jul 17 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
SCHEDULE 13G Thu Jul 02 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov
SCHEDULE 13G/A Thu Jul 02 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov
SCHEDULE 13G Fri Jun 26 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov

All filings

Timeline

filing 10/14/2026 8-K filed
filing 10/6/2026 25-NSE filed
filing 9/22/2026 8-K filed
revenue 9/21/2026 Revenue reported: $3K, year ended Dec 31, 2025
revenue 9/21/2026 Revenue reported: $134K, year ended Dec 31, 2024
revenue 9/21/2026 Revenue reported: $645K, year ended Dec 31, 2023
revenue 9/21/2026 Revenue reported: $934K, year ended Dec 31, 2022
revenue 9/21/2026 Revenue reported: $105K, year ended Dec 31, 2021
revenue 9/21/2026 Revenue reported: $12K, quarter ended Mar 31, 2026
revenue 9/21/2026 Revenue reported: $425, quarter ended Dec 31, 2025 (derived)

Company reliability

–

No resolved statements yet.

Revenue

Quarterly

Mar 2026 $12K
Dec 2025 $425 derived
Sep 2025 $748
Jun 2025 $1K

Annual

FY 2025 $3K
FY 2024 $134K
FY 2023 $645K

Source: SEC XBRL

CEO compensation

$500K (FY 2025) · 156.5x revenue

Amro Albanna (current CEO) - $4.0M total disclosed since 2020

Amro Albanna

10-K

Provisional - extracted from filings, not verified.

FY 2024 $500K extracted
FY 2023 $519K extracted

Notes & debt

Provisional - extracted from filings, not verified.

IN DEFAULT · $4.6M in arrears
$3.2M — 6% 10-Q · 2026-05-20

Quote

March Note On March 11, 2026, the Company entered into a Note Purchase Agreement (the “March Note Purchase Agreement”) with the several buyers (the “March Note Buyers”), pursuant to which the Company will issue its 10 % original issue discount promissory notes (the “March 2026 Notes”) for the aggregate principal amount of $ 3,194,444 .
$1.4M — 8% 10-Q · 2026-05-20

Quote

On June 26, 2025, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with Evofem Biosciences, Inc. (“ Evofem ”), pursuant to which the Company purchased (i) a senior subordinated convertible note (the “ Evofem Note ”) of Evofem in the principal amount of $1,423,076.92, and (ii) a warrant (the “ Evofem Warrant ”) to purchase up to 92,407,592 shares of Evofem common stock for a purchase price of $925,000.
NEARING / AGED
$1.3M — 10% 10-Q · 2026-05-20

Quote

Issuance of Note On April 10, 2026, the Company issued and sold senior unsecured promissory notes (each, a “Note,” and collectively, the “Notes”) to accredited investors in the aggregate original principal amount of $ 1,250,000 for an aggregate purchase price of $ 1,000,000 , reflecting an aggregate original issue discount of $ 250,000 .
OTHER ISSUANCES
$19 — 10-Q · 2026-05-20

Quote

The July 2024 Senior Notes warrants were repriced to $ 18.63 and the number of shares issuable upon exercise of such warrants was increased by 248,568 shares as a result of the reprice provisions.
$0 — 10-Q · 2026-05-20

Quote

Warrant Reprice The August Exchange Agreement, July 2024 Senior Notes, May PIPE, and May PIPE Placement Agent Warrants, (collectively, the “Repriced Outstanding Warrants”) contain full-ratchet anti-dilution provisions whereby the exercise price is adjusted downward in the event the Company issues equity securities at an effective price lower than the warrants’ then-current exercise price.
No notes match this filter.

Top predictors

No resolved predictions on $ADTX yet.

Upcoming resolutions

Nothing awaiting resolution.